Start here if you're new
what it is
Rein develops experimental lung drugs for rare diseases with few or no approved treatments.
how it gets paid
Last year Rein Therapeutics made $0 in revenue.
what just happened
The latest quarter showed $0 in revenue and a $0.74 loss per share.
At a glance
C++ balance sheet — some cracks in the foundation
65/100 earnings predictability — reasonably predictable
-$2.17 fy2024 eps est
1.4 beta
~$34M market cap
xvary composite: 34/100 — weak
What they do
Rein develops experimental lung drugs for rare diseases with few or no approved treatments.
The moat is not revenue. It is scarcity. Rein is chasing rare lung diseases with no approved or limited effective treatments, and you get 2 clinical shots instead of a crowded copycat race. Four employees keep the machine tiny, so every patient enrolled matters.
How they make money
$0
annual revenue
The products that matter
Phase 2 fibrosis drug candidate
LTI-03
sole clinical asset · $0 revenue today
it's the only asset carrying the equity story, and it still supports a ~$34M market cap despite $0 revenue. the latest concrete regulatory win on the page is orphan drug designation in Europe on Jan. 20, 2026.
one asset, one story
Key numbers
$34M
market cap
A $34M company can swing on one trial result. That is the whole game here.
5/100
price stability
A 5/100 score means the chart can lurch on thin news.
1.4
beta
A 1.4 beta means the stock tends to move about 40% harder than the market.
4
employees
With 4 employees, there is no army here. There is a skeleton crew and 2 clinical bets.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for RNTX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest quarter showed $0 in revenue and a $0.74 loss per share.
EDGAR showed $0 revenue and -$0.74 EPS for the latest quarter. There is no sales base, so the company is still funding trials, not a business.
$0
revenue
-$0.74
eps
n/a
n/a
revenue
Revenue was $0, so every dollar of spending still comes from financing and not customers.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Phase 2 failure for LTI-03 in idiopathic pulmonary fibrosis.
med
Single-asset clinical failure
LTI-03 is the whole story on this page. With one Phase 2 asset and $0 revenue, a weak trial outcome would hit the core thesis directly.
The current ~$34M equity value has no second engine to lean on if the data disappoints.
med
Cash burn and dilution
The company has $0 revenue and a return on equity of -83.28%. That usually means future funding matters as much as future science.
If new capital is raised before the clinical story improves, your ownership can shrink before the business ever exists.
med
Execution and governance noise
A board resignation on Feb. 16, 2026 adds one more variable to a company that already has very little room for operational drift.
In a single-program biotech, management stability matters because every decision routes back to one trial path.
All three risks point at the same fact: 100% of the current equity story sits on one Phase 2 program while the company has no operating revenue to absorb mistakes.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
Phase 2 readout for LTI-03
No result date is shown on this page. That's still the event that matters most because one asset supports the whole valuation.
numbers
The cash burn behind the EPS line
A -$0.22 EPS estimate for the next report will not tell you if the drug works, but it will tell you whether the balance sheet pressure is easing or getting worse.
funding
Any sign of a fresh capital raise
With $0 revenue and a C++ balance sheet, financing is not background noise. It is part of the thesis.
signal
Whether orphan designation turns into momentum
The Jan. 20, 2026 European orphan designation is useful, but only if it is followed by better data, cleaner development progress, or stronger partnering credibility.
Analyst rankings
earnings predictability
65 / 100
in human-speak, analysts can model the spending better than they can model the outcome because there is no revenue stream yet.
beta
1.4
Beta measures market sensitivity. Here, it means the stock has tended to swing harder than the broader market.
risk rank
5
Safer than 5% of stocks means riskier than most of the market. That fits a pre-revenue, single-asset biotech perfectly well.
source: institutional data
Institutional activity
institutional ownership data for RNTX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive